CDKN2A and non-small cell lung carcinoma: Not all of the identified genetic abnormalities in NSCLC (KRAS, SOX2, CDKN2A, and TP53) are currently targetable by small molecule inhibitors or monoclonal antibodies [11, 13, 28].